The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.
J. Randolph Hecht
Research Funding - GlaxoSmithKline
Yung-Jue Bang
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Shukui Qin
No relevant relationships to disclose
Hyun-Chul Chung
No relevant relationships to disclose
Jian-Ming Xu
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Krzysztof Jeziorski
No relevant relationships to disclose
Yaroslav Shparyk
Research Funding - GlaxoSmithKline
Paulo M. Hoff
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Alberto F. Sobrero
Honoraria - Bayer; Roche; Sanofi
Pamela Salman
No relevant relationships to disclose
Jin Li
No relevant relationships to disclose
Svetlana Protsenko
No relevant relationships to disclose
Marc E. Buyse
Employment or Leadership Position - IDDI
Stock Ownership - IDDI
Karen Afenjar
No relevant relationships to disclose
Tomomi Kaneko
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Allison Kemner
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Sergio Santillana
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Michael F. Press
Consultant or Advisory Role - Genentech; GlaxoSmithKline; Halozyme Therapeutics ; NanoString Technologies; Roche; Ventana Medical Systems
Honoraria - Genentech; GlaxoSmithKline; Halozyme Therapeutics ; NanoString Technologies; Roche; Ventana Medical Systems
Research Funding - Roche/Genentech
Dennis J. Slamon
Consultant or Advisory Role - Novartis; Sanofi
Stock Ownership - Amgen; Pfizer